CNP Aquaporin 4
Alternative Names: CNP-Aquaporin-4; TIMP-AntigenLatest Information Update: 28 Jul 2023
At a glance
- Originator Cour Pharmaceutical Development
- Class Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuromyelitis optica
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for research development in Neuromyelitis-optica in USA
- 27 Jun 2019 Early research in Neuromyelitis optica in USA before June 2019 (Cour Pharmaceutical Development pipeline, June 2019)